Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...

Full description

Bibliographic Details
Main Authors:	Fionnuala Crowley, MB BCh BAO, Bailey G. Fitzgerald, MD, Aarti S. Bhardwaj, MD, Irine Siraj, MD, Cardinale Smith, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	JTO Clinical and Research Reports
Subjects:	Osimertinib Myositis NSCLC EGFR Case report
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364321001193

Similar Items

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
by: Hsu-Yuan Chen, et al.
Published: (2024-10-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC
by: Jiaxin Liu, et al.
Published: (2024-11-01)

Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
by: Clayton P. Smith, MD, et al.
Published: (2023-03-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report
by: Hailey M. Hirata, PharmD, et al.
Published: (2025-04-01)

Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study
by: Liu Q, et al.
Published: (2023-11-01)

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
by: Wang L, et al.
Published: (2023-10-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review
by: Alexander S Watson, et al.
Published: (2025-03-01)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Shanliang Hu, et al.
Published: (2022-08-01)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
by: Zhang SS, et al.
Published: (2022-04-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
by: Alberto P. Romagnolo, et al.
Published: (2023-06-01)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
by: Richard E. Kast, et al.
Published: (2021-05-01)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
by: Lei Wen, et al.
Published: (2023-08-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01)

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
by: Atul Tiwari, et al.

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01)

Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC
by: Brandon S. Imber, MD, MA, et al.
Published: (2023-12-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
by: Fei Ren, et al.
Published: (2022-08-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
by: Elizabeth Marrett, et al.
Published: (2024-07-01)

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
by: Hirotsugu Kenmotsu, MD, PhD, et al.
Published: (2024-11-01)

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
by: Kageaki Watanabe, MD, et al.
Published: (2024-11-01)

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
by: Taisuke Ito, et al.
Published: (2024-01-01)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
by: Rui Han, et al.
Published: (2020-06-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
by: William Tompkins, MD, et al.
Published: (2024-08-01)